NZ709525A - Delayed-release composition comprising biguanide - Google Patents
Delayed-release composition comprising biguanideInfo
- Publication number
- NZ709525A NZ709525A NZ709525A NZ70952514A NZ709525A NZ 709525 A NZ709525 A NZ 709525A NZ 709525 A NZ709525 A NZ 709525A NZ 70952514 A NZ70952514 A NZ 70952514A NZ 709525 A NZ709525 A NZ 709525A
- Authority
- NZ
- New Zealand
- Prior art keywords
- biguanide
- delayed
- release composition
- pharmacokinetics
- risk
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940123208 Biguanide Drugs 0.000 title abstract 2
- 230000003111 delayed effect Effects 0.000 title abstract 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 1
- -1 biguanide compound Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361749307P | 2013-01-05 | 2013-01-05 | |
PCT/US2014/010240 WO2014107617A1 (en) | 2013-01-05 | 2014-01-03 | Delayed-release composition comprising biguanide |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ709525A true NZ709525A (en) | 2020-07-31 |
Family
ID=50030486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ709525A NZ709525A (en) | 2013-01-05 | 2014-01-03 | Delayed-release composition comprising biguanide |
Country Status (19)
Country | Link |
---|---|
US (2) | US20140193498A1 (en) |
EP (1) | EP2941245B1 (en) |
JP (1) | JP6333855B2 (en) |
KR (1) | KR102229492B1 (en) |
CN (2) | CN105101956B (en) |
AR (1) | AR094374A1 (en) |
AU (1) | AU2014203942B2 (en) |
CA (1) | CA2896864C (en) |
CL (1) | CL2015001914A1 (en) |
CU (1) | CU20150071A7 (en) |
EA (1) | EA039530B1 (en) |
HK (1) | HK1214966A1 (en) |
IL (1) | IL239722B (en) |
MX (2) | MX2020011594A (en) |
NZ (1) | NZ709525A (en) |
PH (1) | PH12015501520A1 (en) |
SG (2) | SG11201505240QA (en) |
WO (1) | WO2014107617A1 (en) |
ZA (1) | ZA201504858B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
EA039943B1 (en) | 2011-01-07 | 2022-03-30 | Анджи Фарма (Юс) Элэлси | Method for lowering blood glucose levels in a subject |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
JP2015503582A (en) | 2012-01-06 | 2015-02-02 | エルセリクス セラピューティクス インコーポレイテッド | Biguanide compositions and methods of treating metabolic disorders |
EP2800562A2 (en) | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
HUE061809T2 (en) * | 2014-12-24 | 2023-08-28 | Principia Biopharma Inc | Compositions for ileo-jejunal drug delivery |
CA2990230A1 (en) * | 2015-06-19 | 2016-12-22 | University Of Southern California | Compositions and methods for modified nutrient delivery |
WO2016205701A1 (en) | 2015-06-19 | 2016-12-22 | University Of Southern California | Enteral fast access tract platform system |
WO2018132768A1 (en) * | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
FR3068601B1 (en) * | 2017-07-05 | 2021-02-19 | Eric Joseph Marie Fulgence Janin | USE OF IMEGLIMINE FOR THE PREVENTION AND / OR TREATMENT OF HEPATOCELLULAR CARCINOMA |
US20220354800A1 (en) * | 2019-06-03 | 2022-11-10 | R.P. Scherer Technologies, Llc | Delayed release softgel capsules |
US20230000820A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS58403B2 (en) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L- Ascorbine Sanseizaino Seizouhou |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2704146B1 (en) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules of acetylsalicylic acid with controlled release. |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
FR2725623A1 (en) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION |
EP1598054B1 (en) | 1997-04-15 | 2011-03-16 | Csir | Non-therapeutic methods of suppressing appetite |
US5891919A (en) | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
ITMI991316A1 (en) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE |
IL132313A0 (en) | 1999-10-11 | 2001-03-19 | Yeda Res & Dev | Leptin assay |
US20110217394A1 (en) | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
MXPA03006217A (en) * | 2001-01-12 | 2004-10-15 | Sun Pharmaceutical Ind Ltd | Spaced drug delivery system. |
WO2002078617A2 (en) | 2001-03-28 | 2002-10-10 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
US8030008B2 (en) | 2001-04-05 | 2011-10-04 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
US20060019346A1 (en) | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
WO2004012715A1 (en) * | 2002-08-02 | 2004-02-12 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
CN1413582A (en) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method |
EP1581555B1 (en) | 2002-12-18 | 2008-04-30 | Givaudan SA | Chimeric alpha q-gustducin g-proteins |
DE10308504A1 (en) | 2003-02-26 | 2004-09-09 | Basf Ag | Enzymatic production of (meth) acrylic acid esters |
WO2005009351A2 (en) | 2003-07-17 | 2005-02-03 | Santé International, Inc. | Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics |
KR20070053659A (en) | 2004-04-20 | 2007-05-25 | 도이체스 인스티튜트 퓌어 에른에룬그스포슝 | Agonists of a bitter taste receptor and uses thereof |
US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
US7829299B2 (en) | 2004-11-18 | 2010-11-09 | Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
CN101166742B (en) | 2005-04-28 | 2011-07-13 | 味之素株式会社 | Novel lactam compound |
US20060269617A1 (en) | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
WO2007002026A2 (en) | 2005-06-22 | 2007-01-04 | Senomyx, Inc. | Identification of human t2r recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators |
NZ566642A (en) * | 2005-08-30 | 2011-11-25 | Piramal Life Sciences Ltd | Extended release pharmaceutical composition of metformin and a process for producing it |
FR2891459B1 (en) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME |
US20070104805A1 (en) | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
JP2007215162A (en) | 2006-01-11 | 2007-08-23 | Canon Inc | Information processing apparatus, control method thereof, program and recording medium |
US20070207227A1 (en) | 2006-02-23 | 2007-09-06 | Conopco, Inc., D/B/A Unilever, A Corporation Of New York | Appetite suppressant compositions |
WO2007116404A2 (en) | 2006-04-10 | 2007-10-18 | Bar-Ilan University | Cucurbitacin glucosides and use thereof in treating cancer |
CA2551706A1 (en) | 2006-06-27 | 2007-12-27 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon |
WO2008019920A1 (en) | 2006-08-17 | 2008-02-21 | Unilever N.V. | Processes for production of hoodia plant extracts containing steroidal glycosides |
EP2054071A1 (en) | 2006-08-24 | 2009-05-06 | Unilever N.V. | Process for preparing a composition comprising steroidal glycosides |
CN101522702A (en) | 2006-09-05 | 2009-09-02 | 塞诺米克斯公司 | Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators |
EP1975612A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
EP1975611A1 (en) | 2007-03-29 | 2008-10-01 | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand | Agonists of bitter taste receptors and uses thereof |
US20090042813A1 (en) | 2007-08-10 | 2009-02-12 | Sergey Michailovich Melnikov | Hoodia extract oil compositions comprising medium chain triglycerides |
WO2009053980A2 (en) | 2007-10-24 | 2009-04-30 | Arava Hoodia Growers A. C. S. Ltd. | An improved appetite suppressant |
JP5075211B2 (en) | 2008-01-29 | 2012-11-21 | 中森製薬株式会社 | Pharmaceutical composition |
EP2300830B1 (en) | 2008-06-13 | 2015-05-20 | Givaudan SA | Methods of identifying modulators of the bitter taste receptor tas2r44 |
JP5539881B2 (en) | 2008-08-29 | 2014-07-02 | サントリーホールディングス株式会社 | Novel epigallocatechin gallate tetramer and vascular endothelial function improving agent containing them |
EP2329271B1 (en) | 2008-08-29 | 2012-06-20 | Givaudan SA | Methods to identify modulators |
WO2010060198A1 (en) | 2008-11-26 | 2010-06-03 | West Central Envirotech Inc. | Composition and method for controlling insects |
EP2385049A4 (en) | 2009-01-03 | 2012-08-08 | Shizuoka Prefecture Public University Corp | Sulfated c-glycoside, method for isolating same and method for synthesizing same |
WO2011012298A1 (en) | 2009-07-28 | 2011-02-03 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof |
ES2437921T3 (en) | 2009-10-21 | 2014-01-15 | Wisconsin Alumni Research Foundation | Method to prevent type 1 diabetes |
WO2011068814A1 (en) | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
EP2345646A1 (en) | 2010-01-14 | 2011-07-20 | InterMed Discovery GmbH | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
US20110293753A1 (en) | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
GB201009873D0 (en) | 2010-06-14 | 2010-07-21 | Univ Leuven Kath | Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium |
EP2397039A1 (en) | 2010-06-21 | 2011-12-21 | Abbott Laboratories | Compositions for delaying progression of diabetes using Salacia oblonga extract |
CN101978956B (en) * | 2010-10-13 | 2012-03-28 | 北京京丰制药有限公司 | Metformin hydrochloride enteric-coated tablets and preparation method thereof |
EA039943B1 (en) * | 2011-01-07 | 2022-03-30 | Анджи Фарма (Юс) Элэлси | Method for lowering blood glucose levels in a subject |
EP2800562A2 (en) * | 2012-01-06 | 2014-11-12 | Elcelyx Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
CN103768071B (en) * | 2012-10-23 | 2016-08-17 | 中国医药工业研究总院 | A kind of oral formulations treating diabetes |
-
2014
- 2014-01-03 NZ NZ709525A patent/NZ709525A/en unknown
- 2014-01-03 JP JP2015551792A patent/JP6333855B2/en active Active
- 2014-01-03 EP EP14702108.3A patent/EP2941245B1/en active Active
- 2014-01-03 MX MX2020011594A patent/MX2020011594A/en unknown
- 2014-01-03 EA EA201591085A patent/EA039530B1/en unknown
- 2014-01-03 SG SG11201505240QA patent/SG11201505240QA/en unknown
- 2014-01-03 SG SG10201705437SA patent/SG10201705437SA/en unknown
- 2014-01-03 CN CN201480003932.XA patent/CN105101956B/en active Active
- 2014-01-03 KR KR1020157019855A patent/KR102229492B1/en active IP Right Grant
- 2014-01-03 CN CN201910033955.XA patent/CN110051638B/en active Active
- 2014-01-03 AU AU2014203942A patent/AU2014203942B2/en active Active
- 2014-01-03 US US14/147,449 patent/US20140193498A1/en active Pending
- 2014-01-03 MX MX2015008625A patent/MX2015008625A/en active IP Right Grant
- 2014-01-03 CA CA2896864A patent/CA2896864C/en active Active
- 2014-01-03 WO PCT/US2014/010240 patent/WO2014107617A1/en active Application Filing
- 2014-01-06 AR ARP140100044A patent/AR094374A1/en not_active Application Discontinuation
-
2015
- 2015-06-30 IL IL239722A patent/IL239722B/en unknown
- 2015-07-03 PH PH12015501520A patent/PH12015501520A1/en unknown
- 2015-07-03 CL CL2015001914A patent/CL2015001914A1/en unknown
- 2015-07-06 CU CUP2015000071A patent/CU20150071A7/en unknown
- 2015-07-06 ZA ZA2015/04858A patent/ZA201504858B/en unknown
-
2016
- 2016-03-15 HK HK16103014.8A patent/HK1214966A1/en unknown
-
2019
- 2019-11-26 US US16/695,498 patent/US20200093750A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL239722A0 (en) | 2015-08-31 |
JP2016504384A (en) | 2016-02-12 |
EA039530B1 (en) | 2022-02-08 |
BR112015016111A2 (en) | 2020-01-28 |
WO2014107617A1 (en) | 2014-07-10 |
KR102229492B1 (en) | 2021-03-17 |
KR20150103079A (en) | 2015-09-09 |
CL2015001914A1 (en) | 2015-09-04 |
SG11201505240QA (en) | 2015-08-28 |
US20140193498A1 (en) | 2014-07-10 |
EA201591085A1 (en) | 2015-12-30 |
CN110051638B (en) | 2022-02-01 |
HK1214966A1 (en) | 2016-08-12 |
AR094374A1 (en) | 2015-07-29 |
CA2896864C (en) | 2021-04-20 |
CN105101956B (en) | 2018-12-07 |
EP2941245A1 (en) | 2015-11-11 |
EP2941245B1 (en) | 2024-06-26 |
CN105101956A (en) | 2015-11-25 |
US20200093750A1 (en) | 2020-03-26 |
SG10201705437SA (en) | 2017-07-28 |
JP6333855B2 (en) | 2018-05-30 |
MX2020011594A (en) | 2022-01-13 |
CN110051638A (en) | 2019-07-26 |
ZA201504858B (en) | 2018-12-19 |
CU20150071A7 (en) | 2016-01-29 |
PH12015501520A1 (en) | 2015-09-21 |
AU2014203942A1 (en) | 2015-07-16 |
CA2896864A1 (en) | 2014-07-10 |
AU2014203942B2 (en) | 2019-01-03 |
IL239722B (en) | 2022-04-01 |
MX2015008625A (en) | 2015-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015501520A1 (en) | Delayed-release composition comprising biguanide | |
PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
PL3577110T3 (en) | 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors | |
HK1219432A1 (en) | Pharmaceutical composition having pyrimidine compound as active ingredient | |
PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
EA033555B1 (en) | Pharmaceutical compositions for treating sickle cell disorder | |
MX2016000675A (en) | Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof. | |
PH12015501096A1 (en) | Composition for immediate and extended release | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
MX2016013431A (en) | Pharmaceutical compositions comprising antibacterial agents. | |
MX2019012454A (en) | Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin- 2-yl)-1h-pyrazol-5-ol hydrochloride. | |
MX363530B (en) | Tricyclic benzoxaborole compound, preparation method therefor, and use thereof. | |
WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
MX2017009289A (en) | Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same. | |
EP3184113A4 (en) | Pharmaceutical composition, comprising gold compound, for preventing or treating liver fibrosis or liver cirrhosis | |
EP3682016A4 (en) | Formulations for compound delivery | |
MX2017008983A (en) | Sulfonamide pharmaceutical composition. | |
EP3181137A4 (en) | Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3 | |
WO2014166836A8 (en) | Growth hormone compound formulation | |
WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
EP3260121A4 (en) | Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient | |
MX2016013439A (en) | Solid forms of a pharmaceutically active compound. | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
IN2013MU03308A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ASS | Change of ownership |
Owner name: ANJI PHARMA (US) LLC, US Effective date: 20190913 |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JAN 2022 BY CPA GLOBAL Effective date: 20201119 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JAN 2023 BY CPA GLOBAL Effective date: 20211118 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JAN 2024 BY CPA GLOBAL Effective date: 20221119 |
|
ASS | Change of ownership |
Owner name: ANJI PHARMACEUTICALS INC., US Effective date: 20230119 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JAN 2025 BY CPA GLOBAL Effective date: 20231116 |